Butylated Hydroxytoluene vs Blue Dye 2: which is worse?

What is Butylated Hydroxytoluene?

Butylated hydroxytoluene (BHT) is a synthetic lipophilic phenolic antioxidant preservative derived from petroleum. It is a white crystalline solid with chemical formula C15H24O. Like BHA, it prevents fat oxidation and is widely used in food, cosmetics, pharmaceuticals, jet fuel, and rubber.

What is Blue Dye 2?

Blue Dye 2 (Indigotine/Indigo Carmine) is a synthetic disulfonated derivative of indigo. Unlike natural indigo from the indigo plant, the FD&C version is synthetically manufactured from petroleum. It produces a dark royal blue to indigo color and is used in food, pharmaceuticals, and medical diagnostics.

Documented risks

Butylated Hydroxytoluene: BHT's carcinogenicity profile is complex and bidirectional. Some NTP bioassays found liver tumors in female mice at high doses, while other studies suggested BHT might inhibit tumor initiation in certain contexts. A 1986 NTP bioassay found liver tumors in female mice but anti-carcinogenic effects in the rat forestomach — making BHT's net carcinogenicity uncertain. IARC has not formally classified BHT in a specific Group due to this conflicting evidence. The NTP notes that BHT's carcinogenicity data are complex. The 'Report on Carcinogens' does not currently list BHT, unlike BHA, but the NTP has noted inconclusive evidence. Potential endocrine disruption: a 2017 study in Environmental Science & Technology found BHT disrupted thyroid hormone levels in female rats. Multiple animal studies have demonstrated weak estrogenic effects. The American Academy of Pediatrics' 2018 policy statement on food additives mentioned BHT as a synthetic preservative warranting reduced childhood exposure. Kellogg's Frosted Flakes in the US contains BHT to preserve freshness; the European version uses mixed tocopherols (vitamin E) instead — a commercially meaningful difference demonstrating feasibility of substitution. Japan banned BHT for food use based on its precautionary approach. The EU restricts it with ADI-based maximum permitted levels.

Blue Dye 2: Animal studies conducted in the 1980s found that high-dose Blue Dye 2 caused brain tumors in male rats. An NTP bioassay (1987) found statistically significant increases in brain gliomas (astrocytomas) in male rats given high doses. The FDA reviewed these findings and determined that the doses far exceeded typical human dietary exposure. Nonetheless, the tumor finding remains in the scientific record as a concerning data point. EFSA's 2010 safety evaluation of Indigo Carmine (E132) reached an unusual conclusion: it could not establish an ADI due to data limitations, including the brain tumor findings. This means EFSA adopted an implicit conservative position — it neither declared Blue 2 safe nor formally banned it, but the absence of an established ADI signals scientific uncertainty. In medical diagnostic use, high intravenous doses of Indigo Carmine can cause hypertension, bradycardia, and in rare cases anaphylaxis. These are dose-specific clinical pharmacological effects, not relevant to dietary consumption at food use levels. Blue 2 was not included in the 2007 Lancet hyperactivity study. Limited direct research links Blue 2 to behavioral effects. The FDA's April 2025 announcement includes Blue 2 in the class of petroleum-based synthetic dyes to be phased out of the US food supply, reflecting updated policy on the category rather than specific new Blue 2 toxicity data.